Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | HTR1D | P28221 | 7/20 | 0.55 |
| ▸ | HTR1B | P28222 | 6/20 | 0.55 |
| ▸ | HTR1A | P08908 | 5/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | HTR2A | P28223 | 2/20 | 0.53 |
| ▸ | HTR2C | P28335 | 2/20 | 0.53 |
| ▸ | HTR7 | P34969 | 2/20 | 0.53 |
| ▸ | HTR5A | P47898 | 2/20 | 0.53 |
| ▸ | HTR6 | P50406 | 2/20 | 0.53 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.53 |
| ▸ | HTR3B | O95264 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2993315 | 1.00 | KMT2A (0.55) | KMT2AHTR1DHTR1BHTR1AALDH1A1 | |
| Hydrochloric Acid SCHEMBL3001041 | 0.99 | KMT2A (0.54) | KMT2AHTR1DHTR1BHTR1AALDH1A1 | |
| SCHEMBL3000105 | 0.90 | HTR1D (0.53) | KMT2AHTR1DHTR1BHTR1AALDH1A1 | |
| SCHEMBL3000108 | 0.90 | HTR1D (0.53) | KMT2AHTR1DHTR1BHTR1AALDH1A1 | |
| SCHEMBL13209506 | 0.89 | HTR1D (0.57) | KMT2AHTR1DHTR1BHTR1AALDH1A1 | |
| SCHEMBL3000908 | 0.88 | HTR1D (0.54) | KMT2AHTR1DHTR1BHTR1AALDH1A1 | |
| SCHEMBL3000905 | 0.88 | HTR1D (0.54) | KMT2AHTR1DHTR1BHTR1AALDH1A1 | |
| SCHEMBL2996022 | 0.86 | HTR1D (0.55) | KMT2AHTR1DHTR1BHTR1AALDH1A1 | |
| SCHEMBL2996024 | 0.86 | HTR1D (0.55) | KMT2AHTR1DHTR1BHTR1AALDH1A1 | |
| SCHEMBL13209530 | 0.82 | HTR1A (0.53) | KMT2AHTR1DHTR1BHTR1AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7786156-B2 | Synthesis methods and intermediates for the manufacture of Rizatriptan | RATIOPHARM GMBH (DE) | 2010-08-31 | — | — | US | disclosed |
| EP-1751104-B1 | SYNTHESIS METHODS AND INTERMEDIATES FOR THE MANUFACTURE OF RIZATRIPTAN | RATIOPHARM GMBH (DE) | 2010-03-24 | — | — | EP | disclosed |
| US-20070123711-A1 | Synthesis methods and intermediates for the manufacture of rizatriptan | RATIOPHARM GMBH (DE) | 2007-05-31 | — | — | US | disclosed |
| EP-1751104-A1 | SYNTHESIS METHODS AND INTERMEDIATES FOR THE MANUFACTURE OF RIZATRIPTAN | ratiopharm GmbH (DE) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005075422-A1 | SYNTHESIS METHODS AND INTERMEDIATES FOR THE MANUFACTURE OF RIZATRIPTAN | RATIOPHARM GMBH (DE) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123711-A1 | Synthesis methods and intermediates for the manufacture of rizatriptan | HTR7, HRH4, CA7 | KMT2A 1089/4885HTR1D 48/4885HTR1B 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.